BioHarvest Sciences (NASDAQ:BHST) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

BioHarvest Sciences (NASDAQ:BHST) released its quarterly earnings data on Tuesday. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01, FiscalAI reports. BioHarvest Sciences had a negative return on equity of 58.30% and a negative net margin of 31.21%. The business had revenue of $7.87 million for the quarter, compared to analysts’ expectations of $9.31 million.

BioHarvest Sciences Stock Performance

NASDAQ BHST traded up $0.01 on Thursday, reaching $1.75. The company had a trading volume of 113,926 shares, compared to its average volume of 35,391. The company’s fifty day moving average is $1.65 and its 200-day moving average is $3.11. The firm has a market capitalization of $34.43 million, a price-to-earnings ratio of -3.37 and a beta of 0.93. BioHarvest Sciences has a 1-year low of $1.37 and a 1-year high of $8.30.

Analysts Set New Price Targets

BHST has been the subject of a number of research reports. Maxim Group lowered their target price on BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Monday, September 14th. Finally, Roth Capital cut their price target on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.50.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc. is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency. The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.